Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826585) titled 'Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection' on Sept. 9.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Corregene Biotechnology Co., Ltd

Condition: Advanced Solid Tumors

Intervention: Drug: CRTKVA11-03 TCR-T Cell Injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 26, 2026

Target Sample Size: 6

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07826585 ...